secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001743881-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials
-----------------------------------------------------------------------------

- Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).
- Attruby (ATTR-CM) net product revenue $146.0M in Q4; 7,804 patient prescriptions as of Feb 20.
- Phase 3 FORTIFY (LGMD2I/R9) met endpoints; 2.6-point NSAD improvement vs placebo at 12 months.
- Phase 3 PROPEL 3 (infigratinib, achondroplasia) met primary endpoint; mean AHV +2.10 cm/year vs placebo.
- Cash $587.5M at Dec 31; completed $632.5M convertible notes Jan 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/0001743881-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001743881-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer